Author Archives: aapadmin

ردود أفعال واسعة على حملة “اليوم السابع”

ردود أفعال واسعة على حملة “اليوم السابع”.. اللحوم المصنعة أخطر من الخمرة والسجائر.. المعهد القومى للتغذية: تحتوى على مواد مسرطنة وملح البارود.. والأطباء: تزيد إصابة الأطفال بالسكر والسرطان – خبراء ينصحون بمشروب سحرى لإزالة السموم من الجسم يشمل القرفة والزنجبيل والجزر والبنجر والعسل والكيوى والتفاح أثارت حملة «اليوم السابع» للتوعية بمخاطر اللحوم المصنعة ردود أفعال

Read More

Monthly News Roundup – October 2016

Merck’s Zinplava Approved to Fend Off Return of Clostridium Difficile Zinplava (bezlotoxumab) has been FDA-approved to reduce the recurrence of Clostridium difficile infection (CDI) in adults who are receiving antibacterial drug treatment for CDI and who are at high risk for CDI recurrence. Zinplava is not an antibacterial and does not treat an active CDI

Read More

FDA Approves Invokamet XR

RARITAN, N.J., September 21, 2016 – Janssen Pharmaceuticals, Inc. (Janssen) announced today the U.S. Food and Drug Administration (FDA) has approved Invokamet XR – a once-daily, fixed-dose combination therapy of canagliflozin and metformin hydrochloride extended-release (XR)—for first-line use as an adjunct to diet and exercise to improve blood glucose control in adults with type 2

Read More

Quality Risk Management

Regardless of whether you are a member of a quality assurance department in the pharmaceutical industry or not, the term quality risk management (QRM) is likely familiar to you. This is because QRM, a systematic process that assesses risk to the quality of a drug product across its lifecycle (quality risk assessment), is also often

Read More

AstraZeneca pulls application for ovarian cancer drug

AstraZeneca is pulling back its application to market ovarian cancer drug cediranib in Europe, marking the end of the line for the drug in combination was chemotherapy. The firm was seeking approval for use of its oral VEGFR inhibitor in combination with platinum-based chemotherapy followed by maintenance monotherapy to treat adult patients with platinum-sensitive relapsed

Read More

Gilead pulls plug on ulcerative colitis drug

Gilead Sciences has pulled the plug on a combined Phase II/III clinical study of GS-5745 testing the investigational anti-MMP9 antibody in patients with moderately to severely active ulcerative colitis. The decision follows a planned interim analysis of unblinded efficacy and safety data by the Data Monitoring Committee, after the first 150 patients of a planned

Read More

FDA expands its authority over tobacco products

According to FDA and other sources, tobacco use is the single largest preventable cause of disease and death in the United States. Ned MilenkovichAs part of its goal to improve public health and protect future generations from tobacco use risk, the FDA has engaged in rulemaking to extend its jurisdictional authority over all products that

Read More

UN signs historic declaration to fight AMR

A historic declaration to combat antimicrobial resistance has been signed by 193 countries at a United Nations General Assembly. Each signatory has agreed that drug resistant infections must be tackled as a priority, in light of projections that, by 2050, 10 million people a year will be dying as a result at a cost to

Read More

ARAB WORLD: OPPORTUNITIES AND RISKS FOR PHARMA

The three primary criteria for a pharmaceutical company to investigate when building a marketing strategy are market size and growth, protection of intellectual property rights and enforcement of said rights. This report provides an insight into these criteria as they relate to the MENA market. Pharmaceuticals market in MENA At close to USD20 billion, the

Read More